Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival

Prostate

Volumn 74, Issue 3, 2014, Pages 225-234

  Sharma, Jaya ^a   Gray, Kathryn P ^a,b   Evan, Carolyn ^a   Nakabayashi, Mari ^a   Fichorova, Raina ^c,d   Rider, Jennifer ^b,c   Mucci, Lorelei ^b   Kantoff, Philip W ^a,d   Sweeney, Christopher J ^a,d,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Hoosier Oncology Group   (United States)

Author keywords

adiponectin; insulin like growth factor; leptin; prostate cancer

Indexed keywords

ADIPONECTIN; LEPTIN; PROSTATE SPECIFIC ANTIGEN; RISEDRONIC ACID; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ASSAY; CANCER PATIENT; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MIDDLE AGED; MULTIPLEX ELECTROCHEMILUMINESCENCE ASSAY; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE;

EID: 84892436174     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22744     Document Type: Article

References (43)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M,. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002; 360: 103-106.
3. Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C,. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459.
4. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group [see comments]. Lancet 1995; 346: 265-269.
5. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS,. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: Differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194.
6. Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM,. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 2011; 29: 726-732.
7. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
8. Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT,. Metabolic syndrome and the risk of prostate cancer in Finnish men: A population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
9. Lund Haheim L, Wisloff TF, Holme I, Nafstad P,. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.
10. Galic S, Oakhill JS, Steinberg GR,. Adipose tissue as an endocrine organ. Mol Cell Endocrinol 2010; 316: 129-139.
11. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, Muzumdar R, Rohan TE, Strickler HD,. The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev 2009; 25: 3-12.
12. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D,. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90: 911-915.
13. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P,. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461-471, W83-W88.
14. Rowlands MA, Gunnell D, Harris R, Vatten LJ, Holly JM, Martin RM,. Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. Int J Cancer 2009; 124: 2416-2429.
15. DiGiovanni J, Kiguchi K, Frijhoff A, Wilker E, Bol DK, Beltran L, Moats S, Ramirez A, Jorcano J, Conti C,. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455-3460.
16. Barnard RJ, Aronson WJ,. Preclinical models relevant to diet, exercise, and cancer risk. Recent Results Cancer Res 2005; 166: 47-61.
17. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, Higgins B, Lokshin A, Troyer D, Hernandez J, Lynch S, Leach RJ, Thompson IM,. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1331-1335.
18. Correia ML, Rahmouni K,. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006; 8: 603-610.
19. Onuma M, Bub JD, Rummel TL, Iwamoto Y,. Prostate cancer cell-adipocyte interaction: Leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-42667.
20. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S,. Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.
21. Bonorden MJ, Rogozina OP, Kluczny CM, Grossmann ME, Grambsch PL, Grande JP, Perkins S, Lokshin A, Cleary MP,. Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice. Nutr Cancer 2009; 61: 265-275.
22. Flanagan J, Gray PK, Hahn N, Hayes J, Myers LJ, Carney-Doebbeling C, Sweeney CJ,. Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol 2011; 22: 801-807.
23. Rudman SMGK, Kasperzyk JL, Pitt M, Giovannucci GL, Harper PG, Loda M, Mucci LA, Sweeney CJ,. Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Clin Oncol, 2012; 30: (suppl; abstr 4555).
24. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, Chen S, Cosentino L, Curtis K, Dezzutti CS, Donoval B, Doncel GF, Donaghay M, Grivel JC, Guzman E, Hayes M, Herold B, Hillier S, Lackman-Smith C, Landay A, Margolis L, Mayer KH, Pasicznyk JM, Pallansch-Cokonis M, Poli G, Reichelderfer P, Roberts P, Rodriguez I, Saidi H, Sassi RR, Shattock R, Cummins JE Jr., Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: A multicenter study. Anal Chem 2008; 80: 4741-4751.
25. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
26. Cox DR,. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
27. Signorello LB, Brismar K, Bergstrom R, Andersson SO, Wolk A, Trichopoulos D, Adami HO,. Insulin-like growth factor-binding protein-1 and prostate cancer. J Natl Cancer Inst 1999; 91: 1965-1967.
28. Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN,. Androgens, growth factors, and risk of prostate cancer: The multiethnic cohort. Prostate 2010; 70: 906-915.
29. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M,. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563-566.
30. Gennigens C, Menetrier-Caux C, Droz JP,. Insulin-like growth factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol 2006; 58: 124-145.
31. Wu JD, Haugk K, Woodke L, Nelson P, Coleman I, Plymate SR,. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006; 99: 392-401.
32. Nyomba BL, Berard L, Murphy LJ,. Free insulin-like growth factor I (IGF-I) in healthy subjects: Relationship with IGF-binding proteins and insulin sensitivity. J Clin Endocrinol Metab 1997; 82: 2177-2181.
33. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR,. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the alpha 5 beta 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA 1993; 90: 10553-10557.
34. Gray A, Aronson WJ, Barnard RJ, Mehta H, Wan J, Said J, Cohen P, Galet C,. Global Igfbp1 deletion does not affect prostate cancer development in a c-Myc transgenic mouse model. J Endocrinol 2011; 211: 297-304.
35. Kiyama S, Morrison K, Zellweger T, Akbari M, Cox M, Yu D, Miyake H, Gleave ME,. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors. Cancer Res 2003; 63: 3575-3584.
36. Uzoh CC, Holly JM, Biernacka KM, Persad RA, Bahl A, Gillatt D, Perks CM,. Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel. Br J Cancer 2011; 104: 1587-1593.
37. Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L,. Insulin-like growth factor binding protein 2: An androgen-dependent predictor of prostate cancer survival. Eur Urol 2005; 47: 695-702.
38. Miyake H, Pollak M, Gleave ME,. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000; 60: 3058-3064.
39. Xu C, Graf LF, Fazli L, Coleman IM, Mauldin DE, Li D, Nelson PS, Gleave M, Plymate SR, Cox ME, Torok-Storb BJ, Knudsen BS,. Regulation of global gene expression in the bone marrow microenvironment by androgen: Androgen ablation increases insulin-like growth factor binding protein-5 expression. Prostate 2007; 67: 1621-1629.
40. Lewitt MS, Hilding A, Ostenson CG, Efendic S, Brismar K, Hall K,. Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men. Diabetologia 2008; 51: 1135-1145.
41. Lopez-Bermejo A, Khosravi J, Fernandez-Real JM, Hwa V, Pratt KL, Casamitjana R, Garcia-Gil MM, Rosenfeld RG, Ricart W,. Insulin resistance is associated with increased serum concentration of IGF-binding protein-related protein 1 (IGFBP-rP1/MAC25). Diabetes 2006; 55: 2333-2339.
42. Kotronen A, Lewitt M, Hall K, Brismar K, Yki-Jarvinen H,. Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity. J Clin Endocrinol Metab 2008; 93: 4867-4872.
43. Wright JL, Stanford JL,. Metformin use and prostate cancer in Caucasian men: Results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617-1622.